LABETALOL HYDROCHLORIDE IN DEXTROSE Drug Patent Profile
✉ Email this page to a colleague
When do Labetalol Hydrochloride In Dextrose patents expire, and what generic alternatives are available?
Labetalol Hydrochloride In Dextrose is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in LABETALOL HYDROCHLORIDE IN DEXTROSE is labetalol hydrochloride. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Labetalol Hydrochloride In Dextrose
A generic version of LABETALOL HYDROCHLORIDE IN DEXTROSE was approved as labetalol hydrochloride by HERITAGE PHARMA on August 3rd, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LABETALOL HYDROCHLORIDE IN DEXTROSE?
- What are the global sales for LABETALOL HYDROCHLORIDE IN DEXTROSE?
- What is Average Wholesale Price for LABETALOL HYDROCHLORIDE IN DEXTROSE?
Summary for LABETALOL HYDROCHLORIDE IN DEXTROSE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 69 |
DailyMed Link: | LABETALOL HYDROCHLORIDE IN DEXTROSE at DailyMed |
Recent Clinical Trials for LABETALOL HYDROCHLORIDE IN DEXTROSE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston Medical Center | Phase 4 |
Marshall University | Phase 2 |
Loma Linda University | N/A |
Pharmacology for LABETALOL HYDROCHLORIDE IN DEXTROSE
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for LABETALOL HYDROCHLORIDE IN DEXTROSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | LABETALOL HYDROCHLORIDE IN DEXTROSE | labetalol hydrochloride | SOLUTION;INTRAVENOUS | 213330-001 | Nov 9, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |